Reach out to us through @TrialsReport on Twitter if you have any feedback, questions or ideas! What’s New Feb 1, 2022 Version 1.0.2 We fixed a bug to make deeplinks open the correct view instead of only the app App Privacy
The ultimate companion for D2's Trials of Osiris. Look up everything on your opponents or yourself and see your game improve!
The ultimate companion for D2's Trials of Osiris. Look up everything on your opponents or yourself and see your game improve!
Hello! We're the people creating Trials Report, Guardian Report, Crucible Report and PUBG Report. If you like us you can support us with coffee.If you support us you will receive our eternal thanks an
肺癌是我国发病率和死亡率第一的恶性肿瘤[1]。虽然近几年来靶向和免疫治疗显著改善了肺癌患者的生存期,但仍有一部分患者无法从中获益。HER2是肿瘤治疗的经典靶点,非小细胞肺癌患者中HER2改变包括基因突变(2%-4%)、基因扩增(10%-20%)和蛋白过表达(6%-35%),HER2突变主要通过下一代测序(NGS)基因检测发现[2]。在...
DESTINY-Lung05 II期临床研究的分析结果显示,优赫得®5.4mg/kg剂量方案的客观缓解率为58.3%;经研究者评估的PFS为10.8 个月。可控的安全性证实了5.4mg/kg是治疗既往...
DESTINY-Lung02是一项全球随机II期试验,旨在评估德曲妥珠单抗治疗HER2m不可切除和/或转移性非小细胞肺癌患者的安全性和疗效,这些患者在接受至少一种抗癌治疗方案(必须包含铂类化疗)期间或之后发生疾病复发或进展。患者按2:1随机接受德曲妥珠单抗5.4mg/kg(n=102)或6.4mg/kg(n=50)。
DESTINY-Lung05 II期临床研究的分析结果显示,优赫得®5.4mg/kg剂量方案的客观缓解率为58.3%;经研究者评估的PFS为10.8个月。可控的安全性证实了5.4mg/kg是治疗既往接受过治疗的HER2突变晚期肺癌患者的最佳剂量。 …
We report here the first prospective evaluation of the prognostic impact of TF in 2 independent precision medicine studies enrolling pts referred to consider their eligibility to early phase trials. Methods: All consecutive adult pts wi...
Reach out to us through @TrialsReport on Twitter if you have any feedback, questions or ideas! What’s New 1 Feb 2022 Version 1.0.2 We fixed a bug to make deeplinks open the correct view instead of only the app App Privacy The developer,Mark Montvai, indicated that the app’s priva...